MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock and...
$8,499,835
(120.96%↑ Y/Y)
Proceeds from exercise of
prefunded warrants
$85
Net cash provided by
financing activities
$7,556,588
(123.56%↑ Y/Y)
Canceled cashflow
$943,332
Increase in cash and cash
equivalents
$5,914,459
(4090.76%↑ Y/Y)
Canceled cashflow
$1,642,129
Issuance costs related to
issuance of common stock
$477,592
(2.78%↑ Y/Y)
something is missing
-$464,670
Payment of finance lease
$1,070
(-45.93%↓ Y/Y)
Accounts payable
$453,801
(1349.97%↑ Y/Y)
Accrued expenses and
other current...
$248,921
(11.43%↑ Y/Y)
Prepaid expenses and
other current assets
-$66,967
(77.02%↑ Y/Y)
Depreciation expense
$28,193
(-22.00%↓ Y/Y)
Amortization of right-of-use
asset
$22,204
(-58.96%↓ Y/Y)
Other non-current
assets
-$4,571
(65.09%↑ Y/Y)
Net cash used in
operating activities
-$1,499,356
(53.71%↑ Y/Y)
Net cash used in
investing activities
-$142,773
Canceled cashflow
$824,657
Net loss
-$2,324,013
(39.18%↑ Y/Y)
Purchase of property and
equipment
$142,773
Back
Back
Cash Flow
Bluejay Diagnostics, Inc. (BJDX)
Bluejay Diagnostics, Inc. (BJDX)
source: myfinsight.com